{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T16:03:47Z","timestamp":1778774627186,"version":"3.51.4"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T00:00:00Z","timestamp":1603238400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Within the class of tyrosine kinase inhibitors (TKIs), which are used for the treatment of numerous advanced cancers, lenvatinib is associated with a higher prevalence of hypertension (HT) compared with other TKIs. In this study, we investigated the effect of lenvatinib on blood pressure (BP) and associated factors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This single-centre, retrospective observational study included 25 consecutive patients treated with lenvatinib for unresectable hepatocellular carcinoma from April 2018 to December 2018 at the study institution. We assessed changes in BP using ambulatory BP monitoring, urinary sodium excretion, kidney function, use of antihypertensive agents and diuretics, and fluid retention following treatment initiation with lenvatinib.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At 1\u2009week after treatment initiation, the mean BP and the percentage of patients with riser pattern significantly increased compared with those at the baseline. Although there were no significant changes at 1\u2009week, urinary sodium excretion (153.4\u2009\u00b1\u200951.7 and 112.5\u2009\u00b1\u200965.0\u2009mEq\/day at 1 and 3\u2009weeks, respectively, P\u2009&amp;lt;\u20090.05) and estimated glomerular filtration rate significantly decreased and the number of patients with fluid retention increased at 3\u2009weeks. Furthermore, patients with fluid retention had significantly higher BP or required more intensive BP treatment compared with those without fluid retention.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Lenvatinib might lead to HT without fluid retention soon after the initiation of treatment, subsequently leading to a reduction in urinary sodium excretion, thereby contributing to a rise in BP by fluid retention.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ckj\/sfaa137","type":"journal-article","created":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T11:14:53Z","timestamp":1592565293000},"page":"325-331","source":"Crossref","is-referenced-by-count":8,"title":["Changes in blood pressure during treatment with the tyrosine kinase inhibitor lenvatinib"],"prefix":"10.1093","volume":"14","author":[{"given":"Kei","family":"Saito","sequence":"first","affiliation":[{"name":"Division of Nephrology and Kidney Center, Kobe University Graduate School of Medicine, Kobe, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7610-1068","authenticated-orcid":false,"given":"Hideki","family":"Fujii","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Kidney Center, Kobe University Graduate School of Medicine, Kobe, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiji","family":"Kono","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Kidney Center, Kobe University Graduate School of Medicine, Kobe, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Hirabayashi","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Kidney Center, Kobe University Graduate School of Medicine, Kobe, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Yamatani","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Kidney Center, Kobe University Graduate School of Medicine, Kobe, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Kidney Center, Kobe University Graduate School of Medicine, Kobe, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Goto","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Kidney Center, Kobe University Graduate School of Medicine, Kobe, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shohei","family":"Komatsu","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takumi","family":"Fukumoto","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Nishi","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Kidney Center, Kobe University Graduate School of Medicine, Kobe, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,10,21]]},"reference":[{"key":"2021020321163646600_sfaa137-B1","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1681\/ASN.2012070690","article-title":"Onconephrology: the latest frontier in the war against kidney disease","volume":"24","author":"Salahudeen","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"2021020321163646600_sfaa137-B2","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1038\/ki.2014.29","article-title":"Onconephrology: the need and the emergence of a subspecialty in nephrology","volume":"85","author":"Abudayyeh","year":"2014","journal-title":"Kidney Int"},{"key":"2021020321163646600_sfaa137-B3","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ctrv.2019.05.004","article-title":"Management of adverse events associated with tyrosine kinase inhibitors: improving outcomes for patients with hepatocellular carcinoma","volume":"77","author":"Rimassa","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"2021020321163646600_sfaa137-B4","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.3390\/ijms17122073","article-title":"Influence of tyrosine kinase inhibitors on hypertension and nephrotoxicity in metastatic renal cell cancer patients","volume":"17","author":"Semeniuk-Wojta\u015b","year":"2016","journal-title":"Int J Mol Sci"},{"key":"2021020321163646600_sfaa137-B5","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/jnci\/djr128","article-title":"Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib","volume":"103","author":"Rini","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"2021020321163646600_sfaa137-B6","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/annonc\/mdn637","article-title":"Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab","volume":"20","author":"Scartozzi","year":"2009","journal-title":"Ann Oncol"},{"key":"2021020321163646600_sfaa137-B7","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1002\/cncr.31344","article-title":"Treatment-emergent hypertension and efficacy in the phase 3 study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT)","volume":"124","author":"Wirth","year":"2018","journal-title":"Cancer"},{"key":"2021020321163646600_sfaa137-B8","doi-asserted-by":"crossref","first-page":"6467","DOI":"10.2147\/OTT.S84625","article-title":"Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer","volume":"9","author":"Lorusso","year":"2016","journal-title":"Onco Targets Ther"},{"key":"2021020321163646600_sfaa137-B9","first-page":"129","article-title":"Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib","volume":"8","author":"Stjepanovic","year":"2014","journal-title":"Biologics"},{"key":"2021020321163646600_sfaa137-B10","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.2147\/CMAR.S191499","article-title":"Treatment-related adverse effects with TKIs in patients with advanced or radioiodine refractory differentiated thyroid carcinoma: a systematic review and meta-analysis","volume":"11","author":"Yu","year":"2019","journal-title":"Cancer Manag Res"},{"key":"2021020321163646600_sfaa137-B11","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"key":"2021020321163646600_sfaa137-B12","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1111\/cas.12826","article-title":"Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer","volume":"106","author":"Kiyota","year":"2015","journal-title":"Cancer Sci"},{"key":"2021020321163646600_sfaa137-B13","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"2021020321163646600_sfaa137-B14","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s00535-016-1263-4","article-title":"Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma","volume":"52","author":"Ikeda","year":"2017","journal-title":"J Gastroenterol"},{"key":"2021020321163646600_sfaa137-B15","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1253\/circj.CJ-88-0020","article-title":"Guidelines for the clinical use of 24 hour ambulatory blood pressure monitoring (ABPM) (JCS2010): \u2013 digest version \u2013","volume":"76","year":"2012","journal-title":"Circ J"},{"key":"2021020321163646600_sfaa137-B16","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/hr.2014.20","article-title":"The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH2014)","volume":"37","author":"Shimamoto","year":"2014","journal-title":"Hypertens Res"},{"key":"2021020321163646600_sfaa137-B17"},{"key":"2021020321163646600_sfaa137-B18","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1440-1681.1993.tb01496.x","article-title":"A simple method for estimating 24 h urinary sodium and potassium excretion from second morning voiding urine specimen in adults","volume":"20","author":"Kawasaki","year":"1993","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"2021020321163646600_sfaa137-B19","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1291\/hypres.29.397","article-title":"Effectiveness of a spot urine method in evaluating daily salt intake in hypertensive patients taking oral antihypertensive drugs","volume":"29","author":"Kawamura","year":"2006","journal-title":"Hypertens Res"},{"key":"2021020321163646600_sfaa137-B20","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Revised equations for estimated GFR from serum creatinine in Japan","volume":"53","author":"Matsuo","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"2021020321163646600_sfaa137-B21","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/1744-9987.12537","article-title":"Hypertension induced by tyrosine-kinase inhibitors for the treatment of renal cell carcinoma in hemodialysis patients: a single-center experience and review of the literature","volume":"21","author":"Nakai","year":"2017","journal-title":"Ther Apher Dial"},{"key":"2021020321163646600_sfaa137-B22","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1161\/HYPERTENSIONAHA.111.173559","article-title":"The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system","volume":"58","author":"Kappers","year":"2011","journal-title":"Hypertension"},{"key":"2021020321163646600_sfaa137-B23","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1161\/HYPERTENSIONAHA.110.168120","article-title":"Contrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humans","volume":"58","author":"Mayer","year":"2011","journal-title":"Hypertension"},{"key":"2021020321163646600_sfaa137-B24","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/ki.2011.288","article-title":"Proteinuria and hypertension with tyrosine kinase inhibitors","volume":"80","author":"Kandula","year":"2011","journal-title":"Kidney Int"},{"key":"2021020321163646600_sfaa137-B25","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/j.1440-1681.1997.tb02099.x","article-title":"Nitric oxide, the kidney and hypertension","volume":"24","author":"Schnackenberg","year":"1997","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"2021020321163646600_sfaa137-B26","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1097\/HJH.0b013e3283309b59","article-title":"Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects","volume":"27","author":"Kappers","year":"2009","journal-title":"J Hypertens"},{"key":"2021020321163646600_sfaa137-B27","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.atherosclerosis.2017.03.039","article-title":"Lenvatinib, an oral multi-kinase inhibitor, -associated hypertension: potential role of vascular endothelial dysfunction","volume":"260","author":"Sueta","year":"2017","journal-title":"Atherosclerosis"},{"key":"2021020321163646600_sfaa137-B28","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.semnephrol.2010.09.007","article-title":"Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker","volume":"30","author":"Robinson","year":"2010","journal-title":"Semin Nephrol"},{"key":"2021020321163646600_sfaa137-B29","doi-asserted-by":"crossref","first-page":"25130","DOI":"10.1074\/jbc.274.35.25130","article-title":"Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1\/KDR activation of c-Src","volume":"274","author":"He","year":"1999","journal-title":"J Biol Chem"},{"key":"2021020321163646600_sfaa137-B30","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1161\/HYPERTENSIONAHA.109.149690","article-title":"Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels","volume":"56","author":"Kappers","year":"2010","journal-title":"Hypertension"},{"key":"2021020321163646600_sfaa137-B31","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1172\/JCI116423","article-title":"Endothelium-derived relaxing factor\/nitric oxide modulates angiotensin II action in the isolated microperfused rabbit afferent but not efferent arteriole","volume":"91","author":"Ito","year":"1993","journal-title":"J Clin Invest"},{"key":"2021020321163646600_sfaa137-B32","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1161\/01.HYP.19.6.770","article-title":"Nitric oxide modulates vascular tone in preglomerular arterioles","volume":"19","author":"Imig","year":"1992","journal-title":"Hypertension"},{"key":"2021020321163646600_sfaa137-B33","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1111\/j.1523-1755.2000.00377.x","article-title":"Role of macula densa nitric oxide and cGMP in the regulation of tubuloglomerular feedback","volume":"58","author":"Ren","year":"2000","journal-title":"Kidney Int"},{"key":"2021020321163646600_sfaa137-B34","first-page":"F606","article-title":"Inhibition of locally produced nitric oxide resets tubuloglomerular feedback mechanism","volume":"267","author":"Thorup","year":"1994","journal-title":"Am J Physiol"},{"key":"2021020321163646600_sfaa137-B35","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1146\/annurev-physiol-012110-142247","article-title":"Regulation of renal NaCl transport by nitric oxide, endothelin, and ATP: clinical implications","volume":"73","author":"Garvin","year":"2011","journal-title":"Annu Rev Physiol"},{"key":"2021020321163646600_sfaa137-B36","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1186\/s12882-018-1074-3","article-title":"Focal segmental glomerulosclerosis lesion associated with inhibition of tyrosine kinases by lenvatinib: a case report","volume":"19","author":"Furuto","year":"2018","journal-title":"BMC Nephrol"},{"key":"2021020321163646600_sfaa137-B37","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3904\/kjim.2014.29.1.40","article-title":"Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea","volume":"29","author":"Baek","year":"2014","journal-title":"Korean J Intern Med"},{"key":"2021020321163646600_sfaa137-B38","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/MD.0000000000000207","article-title":"Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center","volume":"93","author":"Izzedine","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"2021020321163646600_sfaa137-B39","first-page":"15","article-title":"Proteinuria and hypertension in patients treated with inhibitors of the VEGF signalling pathway \u2013 incidence, mechanisms and management","volume":"59","author":"Tesa\u0159ov\u00e1","year":"2013","journal-title":"Folia Biol (Praha)"},{"key":"2021020321163646600_sfaa137-B40","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s11912-012-0242-z","article-title":"VEGF inhibition, hypertension, and renal toxicity","volume":"14","author":"Hayman","year":"2012","journal-title":"Curr Oncol Rep"},{"key":"2021020321163646600_sfaa137-B41","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1159\/000491387","article-title":"Anti VEGF-TKI treatment and new renal adverse events not reported in phase III trials","volume":"7","author":"Paschke","year":"2018","journal-title":"Eur Thyroid J"},{"key":"2021020321163646600_sfaa137-B42","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1016\/j.humpath.2014.05.015","article-title":"Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature","volume":"45","author":"Usui","year":"2014","journal-title":"Hum Pathol"},{"key":"2021020321163646600_sfaa137-B43","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N Engl J Med"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ckj\/article-pdf\/14\/1\/325\/36184681\/sfaa137.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ckj\/article-pdf\/14\/1\/325\/36184681\/sfaa137.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T10:08:45Z","timestamp":1612778925000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/14\/1\/325\/5934069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,21]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,10,21]]},"published-print":{"date-parts":[[2021,2,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfaa137","relation":{},"ISSN":["2048-8513"],"issn-type":[{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,1,1]]},"published":{"date-parts":[[2020,10,21]]}}}